FDA Extends Review of Beren Therapeutics' Niemann-Pick Disease Drug…

Event summary

FDA extends review period for Beren Therapeutics' NDA for adrabetadex by three months, setting new PDUFA target action date to November 17, 2026.
Extension follows FDA classification of Beren's March 2026 response as a Major Amendment to the NDA.
Adrabetadex is under investigation for treating infantile-onset Niemann-Pick disease, type C (I-NPC).
Drug previously received Orphan Drug and Breakthrough Therapy designations from the FDA.

The big picture

The FDA's extension of the review period for adrabetadex reflects the regulatory scrutiny faced by novel therapies targeting rare diseases. Beren Therapeutics' focus on cholesterol trafficking biology positions it within a niche but growing segment of the biotech industry. The strategic significance lies in the potential market impact of adrabetadex, given the severe unmet need in treating infantile-onset Niemann-Pick disease, type C.

What we're watching

Regulatory Dynamics: How the FDA's extended review period will impact Beren Therapeutics' timeline for potential approval of adrabetadex.
Clinical Strategy: Whether Beren can sustain patient access through its Expanded Access Program during the extended review.
Market Positioning: The pace at which Beren can differentiate adrabetadex in the competitive landscape of rare disease therapies.